[1] . CEUS takes advantage of its special features. First, it has a high-contrast and spatial resolution; second, it uses microbubbles (MBs), a blood-pool contrast medium that allows the visualization of tissue vascularization, and third, it allows the dynamic visualization of tumor enhancement, deleting the background tissue signal and permitting dynamic observations on the same plane [1] [2] [3] . Therefore, CEUS is a sensitive imaging method for evaluating the vascularization of pancreatic lesions including both solid masses and cysts. Its high capability to show tumoral vascularization makes CEUS accurate in the study of neoangiogenesis and in the follow-up of residual tumor or recurrence after treatment [2] [3] [4] [5] [6] [7] . The technique is simple, easy and inexpensive compared to CT and MRI, sufficiently noninvasive to be performed on an outpatient basis, and can also be used in patients with renal failure and who are allergic to iodine contrast agents [1, 8] . Therefore, CEUS can significantly improve the accuracy of US, leading to improved identification and characterization in the study of pancreatic lesions [2] [3] [4] [5] [6] [7] . However, today the use of CEUS is not part of the standardized diagnostic algorithm currently applied for pancreatic cancer.
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Technical Background and Examination Protocol
Harmonic MB-specific imaging with low acoustic US pressure is required for CEUS examination. Dynamic observation of the contrast-enhanced phases (early arterial, arterial, pancreatic, portal/venous and late/sinusoidal)
Introduction
The introduction of contrast-enhanced ultrasonography (CEUS) has led to great developments in the diagnostic capabilities of ultrasound (US). Second-generation contrast media have already proven to be useful in the study of the liver, but examination of other abdominal organs, in particular the pancreas, can also benefit from the dynamic study during continuous ultrasonographic scans begins immediately after the injection of a second-generation contrast medium. Sulfur hexafluoride MBs have a mean diameter of 2.5 m, thus allowing them to reach microcirculation [1] . During CEUS, the enhancement reaches its peak between 15 and 20 s after contrast medium injection. Pancreatic parenchymography is, therefore, markedly earlier and shorter than that of the liver because, in contrast to the liver, a portal venous blood supply is absent; afterwards, there is a progressive washout of contrast medium with loss of gland echogenicity [1] .
The technique of CEUS, if applied to the pancreas, should vary according to clinical indications; one major limitation of CEUS is the occasionally restricted image resolution of deep regions and the poor sonographic visualization of the pancreas due to overlying abdominal gas or to large amounts of abdominal fat [1, 2] .
Clinical Applications

Inflammatory Diseases
Acute Pancreatitis CEUS improves the ultrasonographic diagnosis of pancreatic inflammatory diseases; the identification and differential diagnosis of acute pancreatitis and its eventual complications (i.e. pseudocysts) are more reliable than at conventional US [9, 10] . Unfortunately, there are no studies comparing CEUS with CT or MRI in the evaluation and follow-up of acute pancreatitis; in our experience, CT is undoubtedly better than CEUS, in particular in grading the stage of the disease. At CEUS, the pancreatic segment in the course of mild acute pancreatitis shows an increased contrast enhancement due to hyperemia. Severe acute pancreatitis is characterized by the presence of large confluent necrotic areas, and CEUS may improve the identification and ultrasonographic delimitation of the parenchymal necrosis areas, which appear as nonvascular at dynamic imaging [9, 10] .
Pseudocysts
Pseudocysts are common sequelae of severe acute pancreatitis. At imaging, whenever inclusions are present, pseudocysts are more difficult to be differentiated from cystic tumors of the pancreas, especially mucinous cystadenomas [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . CEUS improves the radiological diagnosis thanks to the evaluation of the vascularization of intralesional inclusions. Pseudocysts demonstrate an absence of signal at CEUS, becoming completely and homogeneously anechoic in the dynamic phase; the diagnosis of pseudocyst with intralesional debris is therefore possible [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] .
Chronic Pancreatitis A chronic inflammatory process induces an increase in the degree of fibrosis with a decrease in hyperemia that is typical of acute pancreatitis, and -as a consequence -a decrease in the parenchymography of the gland. CEUS is especially useful in the differential diagnosis of massforming chronic pancreatitis [2, 7, 9] . The comparison between performances of CEUS, CT and/or magnetic resonance cholangiopancreatography is surely difficult and not currently present in the literature.
Mass-Forming Chronic Pancreatitis CEUS can improve US differential diagnosis between mass-forming pancreatitis and pancreatic adenocarcinoma [2, 7, 9] since they share the same feature of hypoechogenicity at basal US. At CEUS, ductal adenocarcinoma remains hypoechoic in all contrast-enhanced phases because of its intense desmoplastic reaction with the relatively poor mean vascular density of the lesion. In contrast, inflammatory masses show a 'parenchymographic' enhancement in the early contrast-enhanced phase with lesional echogenicity similar to that of the surrounding parenchyma; in the late phases, the enhancement decreases with a washout rate similar to that of the rest of the pancreatic gland. In long-standing chronic inflammatory processes, a low-intensity intralesional parenchymography is observed, probably in relation to the amount of the associated fibrosis [2, 7, 9] . CEUS may be an additional arrow at the bow of a radiologist in order to clarify equivocal features at CT or MRI [2] .
Autoimmune Pancreatitis
The US features of autoimmune pancreatitis are very similar to those of focal pancreatitis, even though autoimmune pancreatitis may more frequently involve the entire gland or, at least, present a larger extension and ubiquitous localization. In these cases, US findings are characteristic where echogenicity is markedly reduced, gland volume is increased and the main pancreatic duct is compressed by glandular parenchyma. CEUS of autoimmune pancreatitis shows a fair -often from moderate to marked -enhancement in the early contrast-enhanced phase, though inhomogeneous. These features are related to the thinning of the glandular vessels due to thick lymphocytic infiltration and fibrosis. Contrast medium washout is usually slow but progressive. CEUS findings may be especially useful in the study of focal forms of autoimmune chronic pancreatitis, in which differential diagnosis with ductal adenocarcinoma is a priority, and CT or MRI features are not absolute. Moreover, CEUS is par-ticularly helpful in the follow-up of the disease during steroid therapy [9] [10] .
Neoplastic Diseases
Ductal Adenocarcinoma Ductal adenocarcinoma usually presents at US as a hypoechoic lesion with roughly defined margins. This lesion is usually 'confused' with the adjacent parenchyma, often altering the gland contour or sometimes, when small, being completely included in the gland parenchyma. The mean vascular density is low and often inferior to that of the normal pancreatic parenchyma. At CEUS, ductal adenocarcinoma enhancement is poor in all contrast-enhanced phases and presents as a hypoechoic mass ( fig. 1 ) compared to the adjacent pancreatic tissue; the margins and size of the lesion are more clearly visible, and its relationship with peripancreatic arterial and venous vessels can also be evaluated for local staging [2, 5, 7, 12] . In particular, it is relatively easy to dynamically evaluate the possible infiltration of the vessels focusing the attention on the margins of the pancreatic mass during the arterial and venous phases. No studies in literature make a comparison between the capabilities of CT, endoscopic ultrasound and CEUS in the evaluation of tumor resectability. The degree of differentiation of the adenocarcinoma influences its microvascular density [2, 5, 7, 12] . In our experience, the depiction of tumoral margins at CEUS is more accurate at a low enhancement than at a high enhancement of pancreatic adenocarcinoma [12] because in cases of well-differentiated carcinoma the mass tends to be isovascular compared to the remaining parenchyma, and the margins of the tumor are no longer visualized. In contrast, the evidence of resectability can be accurately obtained by CEUS in the presence of hypovascular pancreatic tumors. Thus, the pattern of enhancement of pancreatic adenocarcinoma influences the depiction of tumoral margins at CEUS [12] .
CT has its primary role in the staging of ductal adenocarcinoma. CEUS may add some value to the regional staging of pancreatic adenocarcinoma, confirming the vascular infiltration or encasement by the neoplasm. Moreover, CEUS may increase the sensitivity and specificity for the identification and characterization of liver metastases. In fact, after studying a pancreatic lesion in the arterial, pancreatic and venous phases, liver metastasis can be detected using the late hepatic contrast-enhanced phase [2] .
Serous Cystic Tumor Serous cystadenoma has a benign biological behavior in the great majority of cases. The most common variety of serous cystadenoma is the microcystic type, macroscopically characterized by multiple small cysts separated by thin septa. The margins are well defined and a central scar may be present. At CEUS, intralesional septa enhancement improves the identification of the microcystic features of the lesion. The less common oligocystic or macrocystic types of serous cystadenoma present features indistinguishable from those of the other macrocystic tumors of the pancreas [3, 11] . CEUS is helpful in the differential diagnosis of serous cystadenoma. These tumors can be managed conservatively in most cases [3] .
Mucin-Producing Tumors
Mucin-producing tumors of the pancreas include mucinous cystic neoplasms and main-duct and branch-duct intraductal papillary-mucinous neoplasms (IPMNs).
Mucinous Cystic Neoplasms
Mucinous cystadenoma (MCA) is usually found in the pancreatic body/tail of the middle-aged woman and can be considered a premalignant lesion. MCA presents as a cystic round mass -multilocular or, less often, unilocular -of variable size; it may present calcifications on the wall or the septa, parietal nodules and papillary vegetations. The unilocular type is less common (and less specific) and is classified for differential diagnosis along with the other cystic lesions of the pancreas, including pseudocysts and the oligocystic variety of serous cystadenoma [3] . Compared to US, CEUS significantly improves the identification of MCA parietal septa and nodules ( fig. 2 ) and, thanks to the dynamic observation of the contrast-enhanced phases, allows demonstration of the enhancement of intracystic septa and nodules, which become hyperechoic and shiney on the lesional background and anechoic in the course of dynamic imaging [2, 3] . In our experience, CEUS compares favorably with MRI in displaying the anatomic features of cystic pancreatic masses seen at transabdominal sonography [3] .
Intraductal Papillary-Mucinous Neoplasms IPMNs are characterized by the production of dense mucin that may fill the main pancreatic duct (ductectatic mucin-hypersecreting variant) or by endoluminal papillary proliferation (papillary-villous variant). They can be divided into 2 classes: central type and branch-duct-type IPMNs. At US, a dilation of the main pancreatic duct is usually demonstrated for the central type of IPMNs that shows highly inhomogeneous cystic masses, upstream of the main pancreatic duct dilation. CEUS examination of the IPMNs may allow identification of intraductal papillary tumoral vegetations, especially in the papillary-villous variant, demonstrating its vascularization in the dynamic phase. However, a final diagnosis of IPMNs by demonstrating the communication between the tumor and the pancreatic duct is difficult, and CEUS cannot substitute for CT or MRI, but can be useful in the followup [2] [3] [4] . In particular, for the branch-duct-type IPMNs, CEUS can be a safe method for evaluating an eventual growth of the cyst or a papillary proliferation, considering that, in this setting, CEUS has the great advantage of being a noninvasive and low-cost technique [3] .
Endocrine Tumors Endocrine tumors normally appear hypervascular at imaging. Differential diagnosis by imaging between endocrine tumors and ductal adenocarcinoma is of paramount importance. At CEUS, different enhancement patterns can be observed in relation to the size of tumors and tumoral vessels. Voluminous endocrine tumors show a rapid, intense enhancement in the early contrast-en- hanced phases, with the exception of necrotic intralesional areas [13] [14] [15] . In moderate-sized neuroendocrine pancreatic tumors, a capillary blush enhancement can be present in the early contrast-enhanced phase [13] [14] [15] . Nonfunctioning neuroendocrine tumors instead can be hypovascularized, depending on the amount of stroma inside the lesion which is dense and hyalinized. However, in some pancreatic neuroendocrine tumors, hypodense at CT, a clear enhancement is visible at CEUS [13] . The high capability of CEUS in demonstrating endocrine tumor vascularization is a result of the high resolution power of state-of-the-art US imaging, combined with the blood pool distribution of the MBs, and real time dynamic manner of depicting vascularization as CT or MRI do not allow.
Workup of Pancreatic Lesions: Why Should We Do CEUS?
The enhancement features of various pancreatic lesions in CT or MRI are well known, but only CEUS is capable of depicting them in real time. As CEUS is more accurate in pancreatic diseases compared to baseline US, it can immediately lead to a better diagnostic workup and treatment planning, in particular prior to CT or MRI.
CEUS is safe and cost-effective, and can better differentiate the solid from the cystic nature of pancreatic lesions, directing the patients to CT if the lesion is solid and to MRI if the lesion is cystic.
The prospect of new indications for CEUS is becoming a reality, especially in pancreatic diseases where the treatment strategy is currently based on CT, MRI, endoscopic ultrasound or a combination of these techniques. Over the last few years at our institution, these examinations have been increasingly complemented and, in some selected cases, substituted by CEUS. Finally, further prospective studies are needed to compare CEUS with other imaging modalities such as CT and MRI in different pancreatic diseases in order to better define its role in their diagnosis, management and follow-up.
